Scarica l'app Stockscreener
13.50
2.24%
-0.31
Dopo l'orario di chiusura:
13.56
0.06
+0.44%
Precedente Chiudi:
$13.81
Aprire:
$13.71
Volume 24 ore:
351.68K
Relative Volume:
1.34
Capitalizzazione di mercato:
$798.97M
Reddito:
-
Utile/perdita netta:
$-168.02M
Rapporto P/E:
-2.9923
EPS:
-4.5116
Flusso di cassa netto:
$-152.10M
1 W Prestazione:
-0.95%
1M Prestazione:
-17.68%
6M Prestazione:
-37.53%
1 anno Prestazione:
+58.64%
Intervallo 1D:
$13.00
$13.73
Intervallo di 1 settimana:
$13.00
$14.13
Portata 52W:
$8.665
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Nome
Dbv Technologies Adr
Settore
Industria
Telefono
33(0)155427878
Indirizzo
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
13.50 | 822.64M | 0 | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Guggenheim | Buy |
| 2025-05-29 | Ripresa | Goldman | Sell |
| 2023-01-04 | Aggiornamento | Societe Generale | Hold → Buy |
| 2022-12-16 | Downgrade | Goldman | Neutral → Sell |
| 2022-05-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-09-14 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-01-22 | Downgrade | Societe Generale | Hold → Sell |
| 2020-11-02 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-08-06 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-17 | Downgrade | Stifel | Buy → Hold |
| 2020-01-09 | Aggiornamento | Stifel | Hold → Buy |
| 2019-12-16 | Iniziato | Citigroup | Buy |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Iniziato | Goldman | Buy |
| 2018-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Downgrade | Jefferies | Buy → Hold |
| 2018-12-20 | Downgrade | Stifel | Buy → Hold |
| 2017-10-31 | Aggiornamento | Societe Generale | Sell → Hold |
| 2017-10-24 | Downgrade | Societe Generale | Buy → Sell |
| 2017-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Iniziato | Deutsche Bank | Buy |
| 2017-03-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2016-09-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-03 | Iniziato | Barclays | Overweight |
| 2015-10-23 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies Plans Viaskin Peanut Launch Prep, If Approved - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks - TradingView
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
DBV Technologies S.A. - Via Ritzau
DBV Technologies posts half-year liquidity contract figures - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
European ADRs Rose In US Trading Late Thursday Morning - Finimize
DBV1 Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index - markets.businessinsider.com
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial - Yahoo Finance
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial - HCP Live
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - The Manila Times
Peanut patch helps allergic kids with asthma and eczema in trial - Stock Titan
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
European ADRs Slip As Nokia And Sequans Lead Declines - Finimize
DBV Technologies Shareholders Approve Governance and Capital Measures - The Globe and Mail
DBV's Moment of Truth: A Patch, a Promise, and a High-Stakes Pitch - BriefGlance
DBV Technologies Announces the Results of its 2026 Combined General Meeting - markets.businessinsider.com
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - The Manila Times
DBV Technologies Announces First Participant Screened in - GlobeNewswire
Peanut-allergic babies enter THRIVE study for skin patch therapy - Stock Titan
European ADRs Tick Higher In US Trading - Finimize
Dbv Technologies Adr Azioni (DBVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dbv Technologies Adr Azioni (DBVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 29 '26 |
Sale |
4.86 |
534 |
2,595 |
144,995 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):